MRNA - Moderna Posts Quarterly Profit Despite Lower Sales From COVID-19 Vaccine | Benzinga
Moderna Inc (NASDAQ:MRNA) shares are trading higher after the company reported fourth-quarter 2023 revenues of $2.81 billion in Spikevax (COVID-19 vaccine), beating the consensus of $2.49 billion.
Net product sales for the fourth quarter of 2023 were $2.8 billion, representing a 43% year-on-year (Y/Y) decline, primarily driven by lower sales volume, partially offset by a higher average selling price.
This led to $6.7 billion in vaccine sales for fiscal 2023, consistent with the previously communicated financial framework of at least $6 billion.
Moderna achieved a 48% cumulative market share in the U.S. retail segment during the fall 2023 ...